Open-access clinical trial registries: the Italian scenario

Trials

Anna Roberto¹  Paola Mosconi¹ 

[1] Laboratory of Medical Research and Consumer Involvement, Mario Negri Institute for Pharmacological Research, Via La Masa 19, 20156, Milan, Italy

关键词: Information;    Citizen;    Clinical trials registry;   

Others  :  1095257
DOI  :  10.1186/1745-6215-13-194

 received in 2011-12-01, accepted in 2012-10-04,  发布年份 2012

【 摘 要 】

Background

Citizens, patients and their representatives are increasingly insisting on working with health professionals to organize and discuss research protocols. The International Committee of Medical Journal Editors recommended setting up a public clinical trial registry where anyone can find key information about a trial. Around the world, governments have, in fact, now begun to legislate mandatory disclosure of all clinical trials. The aims of the present survey were to assess the availability of clinical trial registries for Italian citizens and to examine the transparency of the data items reported.

Methods

The availability of open-access clinical trial registries was surveyed on a sample of 182 websites, including research institutes and centers of excellence (IRCCS-teaching hospitals), hospitals and associations. For each registry we downloaded a sample of two trials to assess the correspondence of the data items reported. Results from the Italian and international registries were compared.

Results

Fifteen percent of the sample had an open-access registry of clinical trials. Comparison of the data items available, in terms of completeness and transparency, from institutional and international registries indicated wide variability.

Conclusions

Italian citizens, patients and their associations have scant access to local registries of clinical trials, and international registries are generally more informative. On the European level, advocacy and lobby actions are needed among citizens and patients to boost the diffusion of open-access clinical trial registries without language barriers, thereby facilitating participation, access to information, and the coordination of clinical research.

【 授权许可】

   
2012 Mosconi and Roberto; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Thornton H: Today's patient: passive or involved? Lancet 1999, 354(Suppl):SIV48.
• [2]Godlee F, Chalmers I: Information about ongoing clinical trials for patients. BMJ 2010, 340:c725.
• [3]Jenkins V, Fallowfield L: Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer 2000, 82:1783-1788.
• [4]O’Connell D, Mosconi P: An active role for patients in clinical research? Drug Dev Res 2006, 67:188-192.
• [5]Stewart RJ, Caird J, Oliver K, Oliver S: Patients' and clinicians' research priorities. Health Expect 2011, 14:439-448.
• [6]Liberati A: Need to realign patient-oriented and commercial and academic research. Lancet 2011, 378:1777-1778.
• [7]Lophatananon A, Tyndale-Biscoe S, Malcolm E, Rippon H, Holmes K, Firkins L, Fenton M, Crowe S, Stewart-Brown S, Gnanapragasam V, Muir K: The James Lind Alliance approach to priority setting for prostate cancer research: an integrative methodology based on patient and clinician participation. Br J Urology Int 2011, 108:1040-1043.
• [8]Staley K: Exploring impact: public involvement in NHS, public health and social care research. http://www.invo.org.uk/pdfs/Involve_Exploring_Impactfinal28.10.09.pdf webcite
• [9]Mosconi P, Colombo C, Villani W, Liberati A, Satolli R: PartecipaSalute: a research project and a training program tailored on consumers and patients. In Healthcare Systems Ergonomics and Patient Safety. Edited by Albolino S, Bagnara S, Bellandi T, Llaneza J, Rosal G, Tartaglia R. London: Taylor & Francis Group; 2011:71-76.
• [10]Hanley B, Truesdale A, King A, Elbourne D, Chalmers I: Involving consumers in designing, conducting, and interpreting randomized controlled trials: questionnaire survey. BMJ 2001, 322:519-523.
• [11]Wyatt K, Carter M, Barnard A, Hawton A, Britten N: The impact of consumer involvement in research: an evaluation of consumer involvement in the London Primary Care Studies Programme. Fam Pract 2008, 25:154-161.
• [12]WMA Declaration of Helsinki: Ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/ webcite
• [13]Roderik F: Viergever. Ghersi D: The quality of registration of clinical trials. PLoS ONE 2011, 6:e14701.
• [14]Willyard C: Pfizer lawsuit spotlights ethics of developing world clinical trials. Nat Med 2007, 13:763.
• [15]De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R: Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Ann Intern Med 2004, 141:477-478.
• [16]De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB: Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Ann Intern Med 2005, 143:146-148.
• [17]Pandolfini C, Bonati M: DEC-net: il registro europeo degli studi clinici pediatrici. I primi 200 protocolli inseriti. G Ital Farm Clin 2005, 19:408-410.
• [18]Watson R: New European online clinical trials register is launched. BMJ 2011, 342:d1994.
• [19]Public online register gives access to information on clinical trials. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/03/news_detail_001228.jsp&mid=WC0b01ac058004d5c1 webcite
• [20]Research Activities. http://www.marionegri.it/mn/en/sezioni/dipartimenti/labInfo22/attRicerca.html webcite
• [21]Pignata S, Scambia G, Savarese A, Breda E, Scollo P, De Vivo R, Rossi E, Gebbia V, Natale D, Del Gaizo F, Naglieri E, Ferro A, Musso P, D'Arco AM, Sorio R, Pisano C, Di Maio M, Signoriello G, Annunziata A, Perrone F: MITO Investigators. safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer 2006, 6:202-207. BioMed Central Full Text
• [22]Mosconi P, Colombo C, Satolli R, Liberati A: PartecipaSalute, an Italian project to involve lay people, patients’ associations and scientific-medical representatives on the health debate. Health Expect 2007, 10:194-204.
• [23]Moja LP, Moschetti I, Nurbhai M, Compagnoni A, Liberati A, Grimshaw JM, Chan AW, Dickersin K, Krleza-Jeric K, Moher D, Sim I, Volmink J: Compliance of clinical trial registries with the World Health Organization minimum data set: a survey. Trials 2009, 10:56. BioMed Central Full Text
• [24]WHO: International Clinical Trials Registry Platform (ICTRP). http://www.who.int/ictrp webcite
• [25]Horden A, Georgiou A, Whetton S, Prgomet M: Consumer e-health: an overview of research evidence and implications for future policy. Health Info Manage J 2011, 40:4-5.
• [26]Dear R, Barratt A, Askie L, McGeechan K, Arora S, Crossing S, Currow S, Tattersall M: Adding value to clinical trial registries: insights from Australian Cancer Trials Online, a website for consumers. Clin Trials 2011, 8:70.
• [27]Tharyan P, Ghersi D: Registering clinical trials in India: a scientific and ethical imperative. Natl Med J India 2008, 21:31-34.
• [28]Dreier G, Hasselblatt H, Antes G, Schumacher M: [The German Clinical Trials Register: reasons, general and technical aspects, international integration]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2009, 52:463-468.
• [29]Hasselblatt H, Dreier G, Antes G, Schumacher M: The German Clinical Trials Register: challenges and chances of implementing a bilingual registry. J Evid Based Med 2009, 2:36-40.
• [30]Clinical Trial Register. http://registro.marionegri.it/frontend_eng/index.php webcite